Guy Jodie E, Wigren Edvard, Svärd Maria, Härd Torleif, Lindqvist Ylva
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
J Mol Biol. 2008 Sep 12;381(4):941-55. doi: 10.1016/j.jmb.2008.06.042. Epub 2008 Jun 20.
Human MCFD2 (multiple coagulation factor deficiency 2) is a 16-kDa protein known to participate in transport of the glycosylated human coagulation factors V and VIII along the secretory pathway. Mutations in MCFD2 or in its binding partner, the membrane-bound transporter ERGIC (endoplasmic reticulum-Golgi intermediate compartment)-53, cause a mild form of inherited hemophilia known as combined deficiency of factors V and VIII (F5F8D). While ERGIC-53 is known to be a lectin-type mannose binding protein, the role of MCFD2 in the secretory pathway is comparatively unclear. MCFD2 has been shown to bind both ERGIC-53 and the blood coagulation factors, but little is known about the binding sites or the true function of the protein. In order to facilitate understanding of the function of MCFD2 and the mechanism by which mutations in the protein cause F5F8D, we have determined the structure of human MCFD2 in solution by NMR. Our results show the folding of MCFD2 to be dependent on availability of calcium ions. The protein, which is disordered in the apo state, folds upon binding of Ca(2+) to the two EF-hand motifs of its C-terminus, while retaining some localized disorder in the N-terminus. NMR studies on two disease-causing mutant variants of MCFD2 show both to be predominantly disordered, even in the presence of calcium ions. These results provide an explanation for the previously observed calcium dependence of the MCFD2-ERGIC-53 interaction and, furthermore, clarify the means by which mutations in this protein result in inefficient secretion of blood coagulation factors V and VIII.
人源MCFD2(多重凝血因子缺乏症2)是一种16 kDa的蛋白质,已知其参与糖基化的人凝血因子V和VIII沿分泌途径的运输。MCFD2或其结合伴侣——膜结合转运蛋白ERGIC(内质网-高尔基体中间腔室)-53发生突变,会导致一种轻度遗传性血友病,称为V因子和VIII因子联合缺乏症(F5F8D)。虽然已知ERGIC-53是一种凝集素型甘露糖结合蛋白,但MCFD2在分泌途径中的作用相对不清楚。已证明MCFD2能结合ERGIC-53和血液凝血因子,但对该蛋白的结合位点或真正功能了解甚少。为了便于理解MCFD2的功能以及该蛋白突变导致F5F8D的机制,我们通过核磁共振(NMR)确定了溶液中人源MCFD2的结构。我们的结果表明,MCFD2的折叠依赖于钙离子的可用性。该蛋白在无辅基状态下无序,在Ca(2+)与其C端的两个EF手基序结合后折叠,而N端仍保留一些局部无序。对MCFD2的两种致病突变变体的NMR研究表明,即使在存在钙离子的情况下,它们也主要是无序的。这些结果解释了先前观察到的MCFD2与ERGIC-53相互作用对钙的依赖性,此外,还阐明了该蛋白突变导致凝血因子V和VIII分泌效率低下的方式。